Petr Vladimirovich Kruglyakov
Directeur Général chez PHARMSYNTHEZ
Profil
Petr Vladimirovich Kruglyakov is currently the Director General at Pharmsynthez PJSC.
He previously worked as the Director-Research & Development at Artgen Biotech PJSC from 2010 to 2011 and as the Executive Director at SynBio LLC from 2013 to 2014.
Dr. Kruglyakov obtained his undergraduate degree from the State University of St. Petersburg.
Postes actifs de Petr Vladimirovich Kruglyakov
| Sociétés | Poste | Début |
|---|---|---|
| PHARMSYNTHEZ | Directeur Général | 01/01/2014 |
Anciens postes connus de Petr Vladimirovich Kruglyakov
| Sociétés | Poste | Fin |
|---|---|---|
SynBio LLC
 SynBio LLC Pharmaceuticals: MajorHealth Technology SynBio LLC engages in original research and introduction of conceptually new medicines. The firm’s medicines help treat diseases like liver disease, cardiovascular disease, acute leukemia, growth hormone deficiency and diabetes milletus. Its work is based on scientific developments and conducted in cutting edge laboratories. The company was founded in 2011 and is headquartered in Moscow, Russian Federation. | Directeur Général | 01/01/2013 |
| HUMAN STEM CELLS INSTITUTE | Directeur Technique/Scientifique/R&D | 01/01/2011 |
Formation de Petr Vladimirovich Kruglyakov
| State University of St. Petersburg | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| HUMAN STEM CELLS INSTITUTE | Health Services |
| PHARMSYNTHEZ | Health Technology |
| Entreprise privées | 1 |
|---|---|
SynBio LLC
SynBio LLC Pharmaceuticals: MajorHealth Technology SynBio LLC engages in original research and introduction of conceptually new medicines. The firm’s medicines help treat diseases like liver disease, cardiovascular disease, acute leukemia, growth hormone deficiency and diabetes milletus. Its work is based on scientific developments and conducted in cutting edge laboratories. The company was founded in 2011 and is headquartered in Moscow, Russian Federation. | Health Technology |
